The stock has a 36-month beta value of 1.49. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CNTA is 84.83M, and at present, short sellers hold a 6.50% of that float. On June 05, 2025, the average trading volume of CNTA was 910.45K shares.
CNTA) stock’s latest price update
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s stock price has gone decline by -6.21 in comparison to its previous close of 13.36, however, the company has experienced a -3.24% decrease in its stock price over the last five trading days. zacks.com reported 2025-06-04 that The consensus price target hints at a 138.8% upside potential for Centessa Pharmaceuticals (CNTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CNTA’s Market Performance
Centessa Pharmaceuticals plc ADR (CNTA) has seen a -3.24% fall in stock performance for the week, with a -7.66% decline in the past month and a -26.12% plunge in the past quarter. The volatility ratio for the week is 4.01%, and the volatility levels for the past 30 days are at 3.39% for CNTA. The simple moving average for the past 20 days is -1.78% for CNTA’s stock, with a -18.14% simple moving average for the past 200 days.
Analysts’ Opinion of CNTA
Many brokerage firms have already submitted their reports for CNTA stocks, with Needham repeating the rating for CNTA by listing it as a “Buy.” The predicted price for CNTA in the upcoming period, according to Needham is $35 based on the research report published on May 28, 2025 of the current year 2025.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see CNTA reach a price target of $30. The rating they have provided for CNTA stocks is “Buy” according to the report published on May 08th, 2025.
Piper Sandler gave a rating of “Overweight” to CNTA, setting the target price at $38 in the report published on March 31st of the current year.
CNTA Trading at -2.77% from the 50-Day Moving Average
After a stumble in the market that brought CNTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.36% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNTA starting from Weinhoff Gregory M, who sale 10,000 shares at the price of $12.82 back on May 27 ’25. After this action, Weinhoff Gregory M now owns 122,279 shares of Centessa Pharmaceuticals plc ADR, valued at $128,225 using the latest closing price.
Weinhoff Gregory M, the Officer of Centessa Pharmaceuticals plc ADR, proposed sale 10,000 shares at $12.82 during a trade that took place back on May 27 ’25, which means that Weinhoff Gregory M is holding shares at $128,225 based on the most recent closing price.
Stock Fundamentals for CNTA
The total capital return value is set at -0.39. Equity return is now at value -74.29, with -52.20 for asset returns.
Based on Centessa Pharmaceuticals plc ADR (CNTA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -19.96. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -41.79.
Currently, EBITDA for the company is -221.97 million with net debt to EBITDA at 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.37.
Conclusion
To sum up, Centessa Pharmaceuticals plc ADR (CNTA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
